Welcome to CSNpharm! For Research Use Only!
Bcr-Abl
| Cat. No. | Product Name | CAS No. | Information |
|---|---|---|---|
| CSN15826 | ZM 306416 | 690206-97-4 | ZM-306416 is an inhibitor of VEGFR (Flk-1 or KDR) and Flt with IC50 of 100 nM and 2 μM. It also shows inhibition activity against Src and Abl with IC50 values of 0.33μM and 1.3μM, respectively. |
| CSN16658 | Degrasyn | 856243-80-6 | WP1130 is a selective small molecular deubiquitinase USP5 UCH-L1 USP9x USP14 and UCH37 inhibitor and a BcrAbl destruction pathway activator with an IC50 of 18 M for K562 cells |
| CSN28459 | SIAIS178 | 2376047-73-1 | SIAIS178 is a potent and selective BCR-ABL degrader based on PROTAC technology with an IC50 of 24 nM. SIAIS178 causes effective degradation of BCR-ABL protein by recruiting Von Hippel-Lindau (VHL) E3 ubiquitin ligase. SIAIS178 has anticancer activity. |
| CSN18591 | Radotinib | 926037-48-1 | Radotinib is a selective BCR-ABL1 inhibitor with IC50 of 34 nM also inhibits platelet-derived growth factor receptor PDGFR is used to treat cancers and Chronic Myeloid Leukemia |
| CSN22517 | N-Deshydroxyethyl Dasatinib | 910297-51-7 | PROTAC Bcr-Abl-binding moiety 1 is a Dasatinib-based warhead ligand for conjugation reactions of PROTAC targeting on Bcr-Abl. |
| CSN23049 | PPY-A | 875634-01-8 | PPY A is a potent inhibitor of T315l mutant and wild-type Abl kinases with IC50s of 9 and 20 nM, respectively. |
| CSN12687 | Ponatinib | 943319-70-8 | Ponatinib is a potent multi-target inhibitor of Abl PDGFR VEGFR2 FGFR1 and Src with IC50 of 037 nM 11 nM 15 nM 22 nM and 54 nM respectively |
| CSN21067 | Ponatinib hydrochloride | 1114544-31-8 | Ponatinib is a multi-targeted kinase inhibitor with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src respectively. |
| CSN32501 | Vamotinib | 1416241-23-0 | PF-114 is a Bcr-Abl1 inhbitor. |
| CSN16663 | NVP-BHG712 | 940310-85-0 | NVP-BHG712 is a specific EphB4 inhibitor with ED50 of 25 nM that discriminates between VEGFR and EphB4 inhibition and also shows activity against c-Raf c-Src and c-Abl with IC50 of 0395 M 1266 M and 1667 M respectively |
| CSN11559 | Nilotinib | 641571-10-0 | Nilotinib is a Bcr-Abl inhibitor with IC50 less than 30 nM in Murine myeloid progenitor cells |
| CSN12295 | Nilotinib monohydrochloride monohydrate | 923288-90-8 | Nilotinib HCl is a Bcr-Abl inhibitor with IC50 < 30 nM. |
| CSN12740 | Lyn-IN-1 | 887650-05-7 | Lyn-IN-1 is a potent and selective dual Bcr-AblLyn inhibitor with potential antineoplastic activity it is an orally bioavailable 2-phenylaminopyrimidine derivative |
| CSN17632 | Olverembatinib | 1257628-77-5 | GZD824 is an orally bioavailable Bcr-Abl inhibitor for Bcr-Abl WT and Bcr-Abl T315I with IC50 of 034 and 068 nM respectively |
| CSN18803 | Olverembatinib dimesylate | 1421783-64-3 | GZD824 dimesylate is an orally bioavailable Bcr-Abl inhibitor for Bcr-Abl WT and Bcr-Abl T315I with IC50 of 034 nM and 068 nM respectively |
| CSN15689 | GNF-7 | 839706-07-9 | GNF-7 inhibits Bcr-Abl WT and Bcr-Abl T315I with IC50 of 133 nM and 61 nM respectively |
| CSN12398 | GNF-5 | 778277-15-9 | GNF-5 is a selective non-ATP competitive inhibitor of Bcr-Abl with IC50 of 220 nM its an analogue of GNF-2 with improved pharmacokinetic properties |
| CSN13825 | GNF-2 | 778270-11-4 | GNF-2 is a highly selective non-ATP competitive inhibitor of oncogenic Bcr-Abl activity IC50 014 M |
| CSN25549 | GMB-475 | 2490599-18-1 | GMB-475 is a degrader of BCR-ABL1 tyrosine kinase based on PROTAC, overcoming BCR-ABL1-dependent drug resistance. GMB-475 reduced viability and increased apoptosis in primary CML CD34+ cells, with no effect on healthy CD34+ cells at identical concentrations. |
| CSN17178 | Flumatinib mesylate | 895519-91-2 | Flumatinib mesylate a derivative of imatinib is a multi-kinase inhibitor with IC50 Values of 12 nM 3076 nM and 2662 nM for c-Abl PDGFR and c-Kit respectively |
| CSN18538 | Flumatinib | 895519-90-1 | Flumatinib is a multi-kinase inhibitor with IC50 Values of 12 nM 3076 nM and 2662 nM for c-Abl PDGFR and c-Kit respectively |
| CSN16096 | DPH | 484049-04-9 | DPH is a potent cell permeable c-Abl activator which displays potent enzymatic and cellular activity in stimulating c-Abl activation |
| CSN13733 | Rebastinib | 1020172-07-9 | DCC-2036 is a conformational control Bcr-Abl inhibitor for Abl1 WT and Abl1 T315I with IC50 of 08 nM and 4 nM also inhibits SRC LYN FGR HCK KDR FLT3 and Tie-2 |
| CSN12769 | Dasatinib monohydrate | 863127-77-9 | Dasatinib is a potent and multi-targeted inhibitor that targets Abl Src and c-Kit with IC50 of 1 nM 08 nM and 79 nM respectively |
| CSN16497 | Dasatinib | 302962-49-8 | Dasatinib is a potent and dual Abl/ Src inhibitor IC50 of < 1 nM/0.8 nM respectively and also inhibits c-Kit (WT)/c-Kit (D816V) with IC50 of 79 nM/37 nM. |
| CSN18475 | Dasatinib hydrochloride | 854001-07-3 | Dasatinib HCl is a potent and dual Abl/ Src inhibitor IC50 of < 1 nM/0.8 nM respectively and also inhibits c-Kit (WT)/c-Kit (D816V) with IC50 of 79 nM/37 nM. |
| CSN28518 | SNIPER(ABL)-039 | 2222354-29-0 | DAS-IAP is a novel PROTAC targeting drug-resistant BCR-ABL. |
| CSN12423 | Danusertib | 827318-97-8 | Danusertib is a pyrrolo-pyrazole and small molecule Aurora kinases inhibitor with IC50 of 13, 79, and 61 nM for Aurora A, B, and C, respectively. It is modestly potent to Abl, TrkA, c-RET and FGFR1, and less potent to Lck, VEGFR2/3, c-Kit, CDK2, etc. |
| CSN27382 | CZC-8004 | 916603-07-1 | CZC-8004 is a pan-kinase inhibitor and binds a range of tyrosine kinases, including ABL kinase. |
| CSN15883 | Agerafenib | 1188910-76-0 | CEP-32496 is an inhibitor of BRAF V600E (IC50 14 nM), WT (IC50 34 nM) and c-Raf (IC50 39 nM). It also exhibits certain inhibitory activity against Abl-1, c-Kit, Ret, PDGFR and VEGFR2. |
| CSN26601 | BCR-ABL-IN-3 | 2240191-12-0 | BCR-ABL-IN-3 is a potent and irreversible Bcr-Abl inhibitor with an IC50 of ≤100 nM for Ba/F3Bcr-AblT3151. BCR-ABL-IN-3 has anti-cancer activity[1]. |
| CSN21248 | BCR-ABL-IN-1 | 188260-50-6 | BCR-ABL-IN-1 is an inhibitor of BCR-ABL tyrosine kinase with a pIC50 of 646 and may be used in the research of chronic myelogenous leukemia |
| CSN19120 | BBT594 | 882405-89-2 | BBT594 is a potentreceptor tyrosine kinase RET inhibitor, used for cancer treatment. |
| CSN19269 | Bafetinib | 859212-16-1 | Bafetinib is a potent and selective dual Bcr-AblLyn inhibitor with IC50 of 5.8 nM19 nM in cell-free assays, does not inhibit the phosphorylation of the T315I mutant and is less potent to PDGFR and c-Kit. |
| CSN18365 | AST 487 | 630124-46-8 | AST-487 is a RET kinase inhibitor with IC50 of 880 nM, inhibits RET autophosphorylation and activation of downstream effectors, also inhibits Flt-3 with IC50 of 520 nM. AST487 also inhibits RET,KDR,c-KIT,and c-ABL kinase with IC50 values below 1 μM. |
| CSN18872 | Asciminib | 1492952-76-7 | Asciminib is a potent and selective allosteric Bcr-Abl inhibitor and inhibits BaF3 cells grown with an IC50 of 025 nM |
| CSN29430 | Vodobatinib | 1388803-90-4 |
+1-708-781-1677
+1-708-286-6026
sales@csnpharm.com
